Sirolimus (Rapamune) for transplant rejection.
D002986:Clinical Trials as Topic; D005252:Fees, Pharmaceutical; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced; D008213:Lymphocyte Activation / Q000187:drug effects; D020123:Sirolimus / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology; D013921:Thrombocytopenia / Q000139:chemically induced
D007166:Immunosuppressive Agents; D020123:Sirolimus